AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody

Weeks after Gilead-partnered Arcus whipped up some cheers from analysts around its small molecule CD73 inhibitor — presenting preliminary data at AACR that “exceeded expectations” — a Chinese biotech is unveiling its own early results using an antibody approach that it says puts more weight behind the target.


Click to view original post